An item in the Oct. 18, 2004, issue of BioWorld Financial Watch mischaracterized one of Salmedix Inc.'s products. SDX-102, l-alanosine, is being tested for brain tumors by a National Cancer Institute consortium in a Phase I/II trial.

Editor's Note: The correction has been made in BioWorld Online.